Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn’s disease of inflammatory type.

Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn’s disease of inflammatory type. J Gastroenterol. 2018 Sep 22;: Authors: Nagata Y, Esaki M, Moriyama T, Hirano A, Umeno J, Maehata Y, Torisu T, Matsumoto T, Kitazono T Abstract BACKGROUND: Anti-tumor necrosis factor (TNF) therapy induces and maintains clinical remission in patients with Crohn’s disease (CD). However, the effect of anti-TNF therapy on the natural course of CD remains controversial. We aimed to investigate the effect of anti-TNF therapy on the initial intestinal surgery for…

Read More

Capsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case-control study.

Capsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case-control study. J Gastroenterol. 2018 Sep 15;: Authors: Esaki M, Matsumoto T, Ohmiya N, Washio E, Morishita T, Sakamoto K, Abe H, Yamamoto S, Kinjo T, Togashi K, Watanabe K, Hirai F, Nakamura M, Nouda S, Ashizuka S, Omori T, Kochi S, Yanai S, Fuyuno Y, Hirano A, Umeno J, Kitazono T, Kinjo F, Watanabe M, Matsui T, Suzuki Y Abstract BACKGROUND: Capsule endoscopy can be used to identify the early stage of small bowel Crohn’s disease (CD). We…

Read More

Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease.

Related Articles Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease. J Gastroenterol. 2018 Aug 30;: Authors: Buisson A, Hordonneau C, Goutorbe F, Allimant C, Goutte M, Reymond M, Pereira B, Bommelaer G Abstract BACKGROUND: Endoscopic mucosal healing is considered as the best therapeutic target in Crohn’s disease (CD) as it is associated with better long-term outcomes. We investigated whether bowel wall healing (BWH) assessed using magnetic resonance imaging (MRI) could predict favorable outcomes and could be a potential…

Read More

Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ).

Related Articles Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ). J Gastroenterol. 2018 Aug 14;: Authors: van der Sloot KWJ, Weersma RK, Dijkstra G, Alizadeh BZ Abstract BACKGROUND: In the complex etiology of inflammatory bowel disease (IBD), the exposome is a major contributor. Though many environmental exposures have been identified, quality of evidence varies greatly and overall evidence for the exposome is inconclusive. A universal, precise, and reproducible measurement tool is needed to study the exposome…

Read More

The state of the art on treatment of Crohn’s disease.

Related Articles The state of the art on treatment of Crohn’s disease. J Gastroenterol. 2018 Jul 06;: Authors: Shi HY, Ng SC Abstract Crohn’s disease (CD) is a chronic, progressive, and destructive disease of the gastrointestinal tract. Although its incidence appears to be stable or decreasing in most countries in the North America and Europe, the incidence is rising rapidly in Asian countries. Immunomodulators and biologics are increasingly used to avoid long-term bowel damage and subsequent disability. Therapeutic drug monitoring facilitates optimizing thiopurines and anti-TNFs use. New biologic agents targeting…

Read More

Crohn’s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan.

Related Articles Crohn’s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan. J Gastroenterol. 2018 Jun 09;: Authors: Yasukawa S, Matsui T, Yano Y, Sato Y, Takada Y, Kishi M, Ono Y, Takatsu N, Nagahama T, Hisabe T, Hirai F, Yao K, Ueki T, Higashi D, Futami K, Sou S, Sakurai T, Yao T, Tanabe H, Iwashita A, Washio M Abstract BACKGROUND: In this study, survival and cause of death were investigated in patients with Crohn’s disease (CD) at a tertiary referral center. METHODS: A database…

Read More

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.

Related Articles NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018 Jun 19;: Authors: Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, Nishida A, Nakagawa S, Miura M, Toyonaga T, Onodera K, Shinozaki M, Ishiguro Y, Mizuno S, Takahara M, Yanai S, Hokari R, Nakagawa T, Araki H, Motoya S, Naito T, Moroi R, Shiga H, Endo K, Kobayashi T, Naganuma M, Hiraoka S, Matsumoto T, Nakamura S,…

Read More

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

Related Articles Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018 Jun 04;: Authors: Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Abstract BACKGROUND: Selective patient recruitment can produce discrepancies between clinical trial results and real-world effectiveness. METHODS: A systematic literature review and meta-analysis were conducted to assess vedolizumab real-world effectiveness and safety in patients with ulcerative colitis (UC) or Crohn’s disease (CD). MEDLINE, MEDLINE In-Process, EMBASE, and Cochrane databases…

Read More

A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing.

Related Articles A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing. J Gastroenterol. 2018 Apr 03;: Authors: Pokrotnieks J, Sitkin S PMID: 29616331 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29616331?dopt=Abstract

Read More

New treatment options for inflammatory bowel diseases.

New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018 Mar 19;: Authors: Verstockt B, Ferrante M, Vermeire S, Van Assche G Abstract The advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD in the last 15 years, but primarily and more importantly secondary loss of response is often observed. Fortunately , new treatment options have been actively explored and some have already entered our clinical practice. In the class of anti-cytokine agents, the anti-IL12/IL23 monoclonal antibodies (mAbs) have entered clinical practice with the anti-p40 mAb ustekinumab in…

Read More
<< Go Back